[A25-32] Nemolizumab (atopic dermatitis) – Benefit assessment according to §35a Social Code Book V
Last updated 07.05.2025
Project no.:
A25-32
Commission:
Commission awarded on 17.02.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission work started
Department/Division:
Drug Assessment
Topic:
Skin and hair
| Project no. | Title | Status |
|---|---|---|
| A25-31 | Nemolizumab (prurigo nodularis) – Benefit assessment according to §35a Social Code Book V | Commission work started |